Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern

Journal of Clinical Pathology

Volumn 61, Issue 2, 2008, Pages 184-191

  Berglund, P ^a   Stighall, M ^a   Jirstrom K ^a   Ryden L ^b   Femo M ^c   Nordenskjold B ^d   Landberg, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PREMENOPAUSE; PRIORITY JOURNAL; TISSUE MICROARRAY; TISSUE SECTION; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER INVASION; CONTROLLED CLINICAL TRIAL; FOLLOW UP; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLIN E; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PREMENOPAUSE; PROGNOSIS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 38849196986     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.047688     Document Type: Article

References (35)

1. Ohtsubo M, Theodoras A, Schumacher J, et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
2. Resnitzky D, Reed S. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 1995;15:3463- 9.
3. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
4. Ekholm-Reed S, Mendez J, Tedesco D, et al. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 2004;165:789-800.
5. Kawamura K, Izumi H, Ma Z, et al. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 2004;64:4800-9.
6. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997;17:453-9.
7. Keyomarsi K, O'Leary N, Molnar G, et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-5.
8. Nielsen NH, Arnerlov C, Emdin SO, et al. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996;74:874-80.
9. Nielsen NH, Arnerlov C, Cajander S, et al. Cyclin E expression and proliferation in breast cancer. Anal Cell Pathol 1998;17:177-88.
10. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
11. Sieuwerts AM, Look MP, Meijer-van Gelder ME, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 2006;12:3319-28.
12. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 2001;32:89-94.
13. Kuhling H, Alm P, Olsson H, et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003;199:424-31.
14. Porter PL, Barlow WE, Yeh IT, et al. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006;98:1723-31.
15. Berglund P, Stighall M, Jirstrom K, et al. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. Cancer Res 2005;65:9727-34.
16. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
17. Pedersen L. Medullary carcinoma of the breast. APMIS Suppl 1997;75:1-31.
18. EBCTGC. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
19. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
20. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
21. Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405-15.
22. McMahon C, Suthiphongchai T, DiRenzo J, et al. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 1999;96:5382-7.
23. Lamb J, Ladha MH, McMahon C, et al. Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 2000;20:8667-75.
24. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9:511S-515S.
25. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002;21:4626-34.
26. Akli S, Zheng PJ, Multani AS, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208.
27. Hui R, Finney GL, Carroll JS, et al. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002;62:6916-23.
28. Span PN, Tjan-Heijnen VC, Manders P, et al. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003;22:4898-904.
29. Ryden L, Jonsson PE, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;41:256-64.
30. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
31. Rudolph P, Kuhling H, Alm P, et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003;105:674-80.
32. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-85.
33. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-8.
34. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-44.
35. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403- 10.